Streetwise Articles By Production Types

Small Cap Joins with Japan Pharma to Advance Next Generation Cancer Treatment

(06/28/2022)

Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates.

Tags: Biotechnology / Pharmaceuticals

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Streetwise Reports (06/27/2022)

Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.

Tags: Biotechnology / Pharmaceuticals

Approval Likely of New Gel for Skin Condition, Analyst Says

Research Report

(06/27/2022)

The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

Research Report

(06/27/2022)

In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.

Tags: Psychedelics

Gene Therapy Co. Releases Data From Huntington's Study

Streetwise Reports (06/23/2022)

Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.

Tags: Biotechnology / Pharmaceuticals

PE Firm to Take Health Tech Co. Private in $1.1B Deal

Streetwise Reports (06/22/2022)

Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash.

Tags: TechnologyHealthcare Services

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

Streetwise Reports (06/22/2022)

Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.

Tags: Biotechnology / Pharmaceuticals

New Positive Data Seem to Support Drug Label Expansion

Research Report

(06/21/2022)

Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.

Tags: Biotechnology / Pharmaceuticals

Results of Dermatitis Clinical Trial Due This Summer

Research Report

(06/21/2022)

Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

New Drug for Heart Failure on Path to Approval, Analyst Says

Research Report

(06/20/2022)

The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

NFL Player Teams With Biopharma Co. to Help SCD Patients

Streetwise Reports (06/17/2022)

Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease.

Tags: Biotechnology / Pharmaceuticals

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Research Report

(06/16/2022)

The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Advances 3 New Clinical Stage Assets

Research Report

(06/16/2022)

Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22

Research Report

(06/14/2022)

These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research.

Tags: Healthcare Services

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Streetwise Reports (06/13/2022)

Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Research Report

(06/10/2022)

Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.

Tags: Biotechnology / Pharmaceuticals

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Research Report

(06/10/2022)

The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Streetwise Reports (06/10/2022)

Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder.

Tags: Biotechnology / Pharmaceuticals

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Research Report

(06/09/2022)

Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

Contributed Opinion

Tim Weintraut (06/08/2022)

After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough.

Tags: Special SituationsRegenerative MedicineBiotechnology / Pharmaceuticals

Biopharma Co. Meets Primary Endpoints in ARDS Trial

Streetwise Reports (06/08/2022)

MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure.

Tags: Biotechnology / Pharmaceuticals

FDA Approves Co.'s New Medical Grade Air Hygiene Device

Streetwise Reports (06/07/2022)

Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgo™ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19.

Tags: TechnologyHealthcare ServicesBiotechnology / Pharmaceuticals

Approved Drug Shows Promise in Follicular Lymphoma

Research Report

(06/06/2022)

Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

FDA Approval of Drug Could Be on the Way

Research Report

(06/03/2022)

"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection.

Tags: Biotechnology / Pharmaceuticals

Bristol Myers to Buy Precision Oncology Co.

Streetwise Reports (06/03/2022)

Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share.

Tags: Biotechnology / Pharmaceuticals

The Life Sciences Report

The Latest Articles from Streetwise Reports

Small Cap Joins with Japan Pharma to Advance Next Generation Cancer Treatment

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Approval Likely of New Gel for Skin Condition, Analyst Says

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

Gene Therapy Co. Releases Data From Huntington's Study

PE Firm to Take Health Tech Co. Private in $1.1B Deal

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

New Positive Data Seem to Support Drug Label Expansion

Results of Dermatitis Clinical Trial Due This Summer

New Drug for Heart Failure on Path to Approval, Analyst Says

NFL Player Teams With Biopharma Co. to Help SCD Patients

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Biotech Co. Advances 3 New Clinical Stage Assets

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Small Biomedical Device Co. Is Ready to Take a Big Step Into Success

Biopharma Co. Meets Primary Endpoints in ARDS Trial

FDA Approves Co.'s New Medical Grade Air Hygiene Device

Approved Drug Shows Promise in Follicular Lymphoma

FDA Approval of Drug Could Be on the Way

Bristol Myers to Buy Precision Oncology Co.

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

More Experts